AstraZeneca PLC has reached a settlement with Teva Pharmaceutical Industries Ltd., the world’s biggest generic drug maker. This will result in a delay of three years generic competition to AstraZeneca’s top-selling drug, the extended-release heartburn treatment Nexium. Teva, which is based in Israel, agreed to keep generic versions of Nexium, the world’s third-best-selling drug by revenue, out of the U.S. market until 2014. Financial terms of the settlement have not been disclosed. Nexium is heavily advertised, touted in TV commercials as “the purple pill” that stops heartburn for 24 hours. Its net sales totaled $7.84 billion in 2008, according to health data firm IMS Health, with roughly $500 million of that going to Merck & Co. under a long-standing marketing partnership.
The settlement, which ends a long-running dispute between the two companies, was reached as a court trial was about to start last month. It also reduces the likely impact of sales from competitive generic drugs on AstraZeneca’s revenue from 2011. Under the settlement, AstraZeneca, has granted Teva a license to enter the U.S. market on May 27, 2014, subject to regulatory approval. Teva has conceded that all patents-at-issue in U.S. litigations are “valid and enforceable.” It also conceded that six Nexium patents would be infringed by the manufacture or sale of Teva’s U.S. generic esomeprazole.
The companies also settled patent litigation over AstraZeneca’s older heartburn drug Prilosec, also known as omeprazole, with Teva agreeing to make a one-time payment to AstraZeneca relating to past sales. Prilosec, which now is available in a nonprescription version, brought AstraZeneca nearly $1.1 billion in sales in 2008. Teva will continue to market omeprazole in the United States. AstraZeneca is under increasing pressure to fill out its thin pipeline of future drugs as generic competition increases, particularly in the United States where it does the bulk of its business.
Source: Associated Press and Forbes
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.